Core EPS in the year up by 7% and by 22% in Q4 2015
Total Revenue growth of 1% in the year, with the gross margin on Product Sales up by 1% point
Top-line and gross-margin growth underpinned continued investment in R&D. Core R&D costs up by 21% in the year, reflecting the investment in the pipeline
Core SG&A costs down by 2% in the year (Q4 2015: down by 11%), in line with commitments
Reported EPS in the year up by 137%, at $0.63 in Q4 2015 (Q4 2014: loss per share of $0.25)
A second interim dividend of $1.90 per share, bringing the dividend for the full year to $2.80; the Board reaffirms its commitment to the progressive dividend policy
FY 2016 CER guidance - a low to mid single-digit percentage decline in Total Revenue and a low to mid single-digit percentage decline in Core EPS; includes dilutive effects from recent transactions
FY 2015 Commercial Highlights
The Growth Platforms grew by 11% in the year, representing 57% of Total Revenue. 'New Oncology' is included for the first time, reflecting its long-term importance for the Company's future growth:
1. Respiratory: +7%, before completion of the acquisition of Takeda's Respiratory business
2. Brilinta/Brilique: +44%, underpinned by a recently-extended US label and positive CHMP opinion
3. Diabetes: +26%, including +76% in Emerging Markets. Global Farxiga/Forxiga growth of 137%
4. Emerging Markets: +12%, including China and Latin America each growing by 15%
5. Japan: +4%, including +8% in Q4 2015
6. New Oncology: Contributed $119m, comprising Lynparza, Iressa (US) and Tagrisso
